SCHEMBL3015686

SCHEMBL3015686

COc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3c(F)c(F)c(F)c(F)c3F)CC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.37
MAPT P10636 5/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
LMNA P02545 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
RECQL P46063 2/20 0.34
HRH3 Q9Y5N1 1/20 0.34
USP2 O75604 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 1/20 0.34
PLA2G2A P14555 1/20 0.34
SCD O00767 1/20 0.34
ALDH1A1 P00352 1/20 0.34
EPHX2 P34913 1/20 0.34
APLNR P35414 2/20 0.34
F2RL3 Q96RI0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004871 0.92 AR (0.39) ARMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3019118 0.89 MAPT (0.41) ARMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3005645 0.88 MAPT (0.40) ARMAPTRAB9ASMN1; SMN2LMNA
SCHEMBL3008685 0.88 MAPT (0.41) ARMAPTRAB9ASMN1; SMN2LMNA
SCHEMBL3013068 0.88 NPC1 (0.36) ARMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3009535 0.87 HTR6 (0.37) ARMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3015365 0.87 MAPT (0.37) ARMAPTHRH3HSD17B10EPHX2
SCHEMBL3006475 0.87 MAPT (0.37) ARMAPTLMNAEPHX2F2RL3
SCHEMBL3006131 0.86 GPR6 (0.40) ARMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3004393 0.86 MEN1 (0.41) ARMAPTSMN1; SMN2LMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885MAPT 18/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.